BEDFORD, Ohio, July 16 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced FDA approval to begin shipping Ceftriaxone for Injection USP. This product is AP rated and is equivalent to Rocephin(R) by Roche. Ceftriaxone is a semisynthetic, broad-spectrum antibiotic used to treat several types of infections caused by susceptible bacteria.
“In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product which represents Bedford’s entry into the cephalosporin market. This continues to demonstrate our commitment to providing a broad based portfolio of products,” said David Gaugh, Vice President and General Manager of Bedford Laboratories.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
In 2008, Boehringer Ingelheim posted net sales of $17 billion (11.6 billion euro) while spending one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
Rocephin(R) is a registered trademark of Hoffmann-La Roche, Inc.
Photo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGOBen Venue Laboratories, Inc.
